Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer Development and Progression: Insight to Therapy

E-ISSN： 2212-6988|3|1|36-62

ISSN： 2212-697x

Source： Clinical Cancer Drugs, Vol.3, Iss.1, 2016-03, pp. : 36-62

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer Development and Progression: Insight to Therapy

Clinical Cancer Drugs, Vol. 3, Iss. 1, 2016-05 ,pp. : 36-62

Bentham Science Publishers

Access to resources Recommend Favorite

Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway

Current Cancer Drug Targets, Vol. 9, Iss. 2, 2009-03 ,pp. : 237-249

Bentham Science Publishers

Access to resources Recommend Favorite

Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer

Current Medicinal Chemistry, Vol. 21, Iss. 26, 2014-09 ,pp. : 3070-3080

Bentham Science Publishers

Access to resources Recommend Favorite

PI3K/Akt/mTOR Intracellular Pathway and Breast Cancer: Factors, Mechanism and Regulation

Current Pharmaceutical Design, Vol. 23, Iss. 11, 2017-05 ,pp. : 1633-1638

Bentham Science Publishers

Access to resources Recommend Favorite

PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress

Current Medicinal Chemistry, Vol. 17, Iss. 35, 2010-12 ,pp. : 4326-4341

Bentham Science Publishers

Access to resources Recommend Favorite